DS: Lower Respiratory Infection Flashcards

(33 cards)

1
Q

Empiric Treatment for
Outpatient - CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CAP Pathogens

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Empiric Treatment for
Outpatient - CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Empiric Treatment for Adult Inpatient - Non severe CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Empiric Treatment for Adult Inpatient - Severe CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Considerations for Treating Adult CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Newer Antibiotic for CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Directed Therapy of CAP in Adult Patients

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Influenza Treatment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Empiric treatment for pediatrics - Outpatient setting CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Empiric treatment for pediatrics - Inpatient setting CAP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Directed therapy for CAP in Pediatric patients

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Influenza Vaccination

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pediatrics CAP common pathogen

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HAP & VAP
Common Pathogen

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Consideration in Selecting Empiric Therapy for HAP

17
Q

Empiric HAP Therapy
Low mortality and MDR risk

18
Q

Consideration in choosing empiric for VAP treatment

19
Q

Empiric VAP Therapy
No MDR Risk and GNR resistance is <10%

20
Q

Empiric VAP Therapy
No MDR Risk and GNR resistance is >10%

21
Q

Empiric VAP Therapy
MDR VAP Risk Factors

22
Q

HAP and VAP - Pathogen Specific
MRSA and PsA

24
HAP and VAP Pathogen Specifici ESBL and AMPc Producing Enterobacterales
25
HAP and VAP Pathogen specific CRE
26
Hap and Vap Pathogen Specific Acinetobacter sp.
27
HAP and VAP Pathogen specific Stenotrophomonas Maltophila
28
Newer Abx for HAP & VAP
29
Newer Abx for HAP/VAP
30
Duration of Abx Therapy HAP & VAP
31
ZEPHyR Study
Vancomycin vs. Linezolid -Linezolid group has greater clinical response, and 60-day mortality -Tx guidelines consider the two drugs for be comparable efficacy despite higher clinical and micro success with linezolid due to study limitation
32
Merino Trial
Zosyn vs. Merrem on CTX resistant E.coli and K.pnuemo - Shows that zosyn may not be equivalent to merrem for serious ESBL infections